Compare Valero Energy Corporation (VLO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Valero Energy Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? Valero Energy Corporation trades at $324.04 (market cap $90.68B), while Vertex Pharmaceuticals Incorporated trades at $529 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Valero Energy Corporation pays a 1.52% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VLO | VRTX | |
|---|---|---|
Market Cap | $90.68B | $132.79B |
Sector | Energy | Health |
52-Week High | $323.92 | $529.65 |
52-Week Low | $133.38 | $376.62 |
Enterprise Value | $94.16B | $126.92B |
Dividend Yield | 1.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Valero Energy (VLO) trades at $298.31, down 1.54% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 29.31% ROE and trades at a P/E of 12.44, below industry averages. Recent news highlights geopolitical tensions supporting refining margins, while Q2 2026 earnings surged on strong refining and renewable diesel performance.
Outlook remains positive with a consensus price target of $324.27, implying 8.7% upside, but risks include volatile oil prices and declining revenue trends. Analyst sentiment is bullish with 55.55% buy ratings, though technical indicators suggest near-term caution amid bearish momentum signals.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
